The COVID-19 Joint Biomanufacturing Subcommittee was a Canadian government advisory group serving as a subcommittee of the COVID-19 Vaccine Task Force, sharing its membership with the COVID-19 Therapeutics Task Force. It was "mandated to make recommendations to the government on various issues relating to the procurement and production of vaccines, including the development of a strategy to boost the country’s biomanufacturing capacity."[1] It met 22 times between June 2020 and February 2021, for "a combined total of about 55 hours."[2]
The first meeting of the subcommittee was on June 23, 2020.[1:1]
| Date | Proposal | Company |
|---|---|---|
| June 23, 2020 | Fill and Finish and Bill of Materials | - |
| June 25, 2020 | National Research Council - Royalmount | Biologics Manufacturing Centre |
| June 29, 2020 | - | Sanofi |
| July 6, 2020 | National Research Council - Royalmount | Biologics Manufacturing Centre |
| July 6, 2020 | Biomanufacturing project | Precision NanoSystems |
| July 6, 2020 | - | KABS Laboratories, Novocol Pharma |
| July 10, 2020 | Biomanufacturing project (follow-up) | Precision NanoSystems |
| July 14, 2020 | Follow-up | KABS Laboratories, Novocol Pharma |
| September 4, 2020 | Follow-up | Sanofi |
| January 21, 2021 | - | Resilience Biotechnologies |
Members of the subcommittee are listed on the Government of Canada's website, along with disclosures of interests.[3]
| Name | Position | Notes |
|---|---|---|
| Mark Lievonen | Co-chair[2:1] | COVID-19 Vaccine Task Force |
| Alan Bernstein | Member | - |
| Cédric Bisson | Member | - |
| Robert Brunham | Member | Applied for a grant from the Strategic Innovation Fund (SIF) |
| Michel de Wilde | Member | Sanofi Pasteur |
| Nancy Harrison | Member | Life Sciences British Columbia |
| Joanne Langley | Member | Dalhousie University, Sanofi |
| Christopher Procyshyn | Member | Vanrx Pharmasystems |
| Benjamin Rovinski | Member | Sanofi |
| Youla Tsantrizos | Member | - |
| Lorne Tyrrell | Member | - |
| Sylvia van den Hurk | Member | Sanofi |
| André Veillette | Member | - |
Lightbound, J. (2023). Domestic Manufacturing Capacity for a COVID-19 Vaccine - Prevention is Better than Cure: Report of the Standing Committee on Industry and Technology (pp. 17–18). House of Commons of Canada. https://web.archive.org/web/20230616022851/https://www.ourcommons.ca/Content/Committee/441/INDU/Reports/RP12496946/indurp14/indurp14-e.pdf ↩︎ ↩︎
Lievonen, M. (2021, February 18). Evidence - INDU (43-2) - No. 18. House of Commons of Canada. https://web.archive.org/web/20240117035228/https://www.ourcommons.ca/DocumentViewer/en/43-2/INDU/meeting-18/evidence#Int-11136052 ↩︎ ↩︎
Innovation, Science and Economic Development Canada. (2022, July 7). COVID-19 Joint Biomanufacturing Subcommittee. Government of Canada. http://archive.today/2024.04.30-223848/https://ised-isde.canada.ca/site/biomanufacturing/en/covid-19-vaccine-task-force/covid-19-joint-biomanufacturing-subcommittee ↩︎